ArticleOncoTargets and therapy2021

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report.

Xinjia Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.